Protocol Ledger

NCT07194382 · Phase II · RECRUITING

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Interventional Phase II clinical trial protocol NCT07194382 sponsored by Avalyn Pharma in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-10 Enrollment: 160 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07194382
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07194382
Protocol FieldVerified Registry Value
NCT IdentifierNCT07194382
Consolidated Lead SponsorAvalyn Pharma
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment160 participants (ESTIMATED)
Registered Start Date2026-03-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07194382
Hospital Research SiteLocationSite Profile
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->
Austin HealthHeidelberg, AustraliaOpen Hospital Dossier ->
The Alfred HospitalMelbourne, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI